BioAtla's BA3182 Shows Promising Safety and Anti-Tumour Activity in Metastatic Adenocarcinoma

Clinical TrialsTherapueticsFDA
Written By Corey Hubbard

Glassbury Cares Podcast

BioAtla's BA3182 Shows Promising Safety and Anti-Tumour Activity in Metastatic Adenocarcinoma
Glassbury Team

Episode #17

Corey Hubbard
Previous

Sodium Channel Blockers: The Non-Opioid Pain Revolution After Vertex's Journavx
Next

Ethical Excellence: Inclusivity & AI in Clinical Research